企业PPT合集

Certain of the statements made in this presentation are forward looking, such as those, among others, relating to the Company’s outlook, including anticipated revenues, costs and expenses, and its potential for growth; the Company’s potential to achieve the noted development and regulatory milestones in 2022 and in future periods, if at all; anticipated activities related to the Company’s planned and ongoing clinical trials; the opportunities for, and the therapeutic and commercial potential of, ADCETRIS®, PADCEV®, TUKYSA®, TIVDAK®, ladiratuzumab vedotin, disitamab vedotin and the Company’s other product candidates and those of its licensees and collaborators; the potential for the Company's products to receive additional global regulatory approvals or label expansions; the Company's pipeline; as well as other statements that are not historical fact. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation: the risks that the Company’s ADCETRIS, PADCEV, TUKYSA and TIVDAK net sales, revenues, expenses, costs, and financial guidance may not be as expected; risks and uncertainties associated with maintaining or increasing sales of ADCETRIS, PADCEV, TUKYSA and TIVDAK due to competition, unexpected adverse events, regulatory action, government pricing and/or reimbursement actions, market adoption by physicians, impacts associated with COVID-19 or other factors; the risks that the Company or its collaborators may be delayed or unsuccessful in planned clinical trial initiations, enrollment in and conduct of clinical trials, obtaining data from clinical trials, planned regulatory submissions, and regulatory approvals in the U.S. and in other countries in each case for a variety of reasons including the difficulty and uncertainty of pharmaceutical product development, negative or disappointing clinical trial results, unexpected adverse events or regulatory actions and the inherent uncertainty associated with the regulatory approval process; and risks related to the duration and severity of the COVID-19 pandemic and resulting global economic, financial and healthcare system disruptions. More information about the risks and uncertainties faced by the Company is contained under the caption “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and the Company’s subsequent periodic reports filed with the SEC. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.